Curaleaf shares fall post FDA’s warning issued over false CBD claims
Category: #health  By Pankaj Singh  Date: 2019-07-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

Curaleaf shares fall post FDA’s warning issued over false CBD claims
  • The FDA warning had come after Curaleaf made unsubstantiated claims that their CBD (cannabidiol) based products can treat serious diseases.
     
  • Curaleaf has been asked to respond within 15 days with its plans to mitigate the violations.

Curaleaf Holdings Inc., (Curaleaf), a medical and wellness cannabis operator in the U.S., has reportedly received a warning from the U.S. Food and Drug Administration (FDA) for marketing CBD products using unsubstantiated claims that they treat serious illnesses.

Curaleaf shares tumbled by as much as 8% after the FDA issued the warning. CBD is a non-intoxicating component of cannabis plant which is said to have health benefits, however, there hasn’t been a lot of research to support these claims yet.

According to reports, The FDA began regulation of CBD in 2018, after hemp was legalized under the Farm Bill, and made it clear that it classifies CBD as a drug since it had been the main ingredient of Epidiolex, America’s only cannabis-based drug that is FDA-approved, to treat serious childhood epilepsy.

The FDA issued the warning letter to Curaleaf for selling prohibited and unauthorized products containing CBD with claims that they treat serious ailments such as Alzheimer’s disease, cancer, pet and pain anxiety and opioid withdrawal among others.

FDA Commissioner Ned Sharpless stated that as the FDA continues to examine pathways for legal marketing of products that contain cannabis and components derived from cannabis, its main motive would still be the promotion and protection of public health. Sharpless further stated that sale of unauthorized products using unsubstantiated claims could put a patient’s life at risk by causing them to avoid crucial medical care.

For the record, FDA has instructed companies to not use CBD in food and beverages, however, it tolerates its presence in topical products until firms don’t make any serious health claims.

Curaleaf has been asked to respond within 15 days with its plans to mitigate the violations. Failure to correct the violations could result in legal action, including confiscation of product and injunction.

Source Credits: https://www.marketwatch.com/story/curaleaf-shares-tumble-8-after-fda-warning-letter-over-cbd-health-claims-2019-07-23

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

CoSara receives Indian regulatory authorization for its five IVDs
CoSara receives Indian regulatory authorization for its five IVDs
By Pankaj Singh

Co-Diagnostics, a renowned US-based molecular diagnostics company, having a patented, unique platform to develop diagnostics tests reportedly announced that CoSara Diagnostics, the company’s JV for production, has received regulatory clearance ...

U.S. government could issue new rules to block shipments to Huawei
U.S. government could issue new rules to block shipments to Huawei
By Pankaj Singh

  Trump administration had issued 75 licenses to allow Huawei suppliers to resume sales U.S. Commerce Department and other authorities focused on utilizing De minimis Rule The U.S. government is reportedly considering new policies to restr...

Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
Cinda finalizes Phase I study of anti-PD-1 / HER2 bispecific antibody
By Pankaj Singh

Cinda Biopharmaceutical, a startup that focuses on treating autoimmune and metabolic diseases, has recently announced the completion of its Phase I clinical study of human epidermal growth factor receptor-2 (HER2) and antibodies against programmed de...